BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 24374027)

  • 1. A new classification system for chronic lung allograft dysfunction.
    Verleden GM; Raghu G; Meyer KC; Glanville AR; Corris P
    J Heart Lung Transplant; 2014 Feb; 33(2):127-33. PubMed ID: 24374027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current views on chronic rejection after lung transplantation.
    Verleden GM; Vos R; Vanaudenaerde B; Dupont L; Yserbyt J; Van Raemdonck D; Verleden S
    Transpl Int; 2015 Oct; 28(10):1131-9. PubMed ID: 25857869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS).
    Verleden SE; Vandermeulen E; Ruttens D; Vos R; Vaneylen A; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM; Verleden GM
    Semin Respir Crit Care Med; 2013 Jun; 34(3):352-60. PubMed ID: 23821509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
    Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
    J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a post-transplant chronic lung allograft dysfunction classification system.
    Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal?
    Verleden GM; Dupont LJ; Van Raemdonck DE
    Eur Respir J; 2005 Feb; 25(2):221-4. PubMed ID: 15684284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.
    Todd JL; Neely ML; Finlen Copeland CA; Frankel CW; Reynolds JM; Palmer SM
    J Heart Lung Transplant; 2019 Feb; 38(2):184-193. PubMed ID: 30466803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?
    Verleden SE; Ruttens D; Vandermeulen E; Vaneylen A; Dupont LJ; Van Raemdonck DE; Verleden GM; Vanaudenaerde BM; Vos R
    Transplantation; 2013 May; 95(9):1167-72. PubMed ID: 23425818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection.
    Vos R; Vanaudenaerde BM; Verleden SE; Ruttens D; Vaneylen A; Van Raemdonck DE; Dupont LJ; Verleden GM
    Transplantation; 2012 Jul; 94(2):101-9. PubMed ID: 22461039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS).
    Sato M; Ohmori-Matsuda K; Saito T; Matsuda Y; Hwang DM; Waddell TK; Singer LG; Keshavjee S
    J Heart Lung Transplant; 2013 May; 32(5):484-91. PubMed ID: 23433813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey.
    Kapila A; Baz MA; Valentine VG; Bhorade SM;
    J Heart Lung Transplant; 2015 Jan; 34(1):65-74. PubMed ID: 25447585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.
    Cooper JD; Billingham M; Egan T; Hertz MI; Higenbottam T; Lynch J; Mauer J; Paradis I; Patterson GA; Smith C
    J Heart Lung Transplant; 1993; 12(5):713-6. PubMed ID: 8241207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obliterative bronchiolitis following lung transplantation: from old to new concepts?
    Verleden GM; Vos R; De Vleeschauwer SI; Willems-Widyastuti A; Verleden SE; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM
    Transpl Int; 2009 Aug; 22(8):771-9. PubMed ID: 19490538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Lymphatic Phenotype of Lung Allografts in Patients With Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome.
    Traxler D; Schweiger T; Schwarz S; Schuster MM; Jaksch P; Lang G; Birner P; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Transplantation; 2017 Feb; 101(2):310-315. PubMed ID: 27163544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
    Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Vanaudenaerde BM; Somers J; Schoonis A; Schaevers V; Van Raemdonck DE; Neyrinck A; Dupont LJ; Yserbyt J; Verleden GM; Vos R
    Am J Transplant; 2016 Jan; 16(1):254-61. PubMed ID: 26372728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy.
    Vanaudenaerde BM; Meyts I; Vos R; Geudens N; De Wever W; Verbeken EK; Van Raemdonck DE; Dupont LJ; Verleden GM
    Eur Respir J; 2008 Oct; 32(4):832-43. PubMed ID: 18827151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lung allograft dysfunction after lung transplantation: the moving target.
    Sato M
    Gen Thorac Cardiovasc Surg; 2013 Feb; 61(2):67-78. PubMed ID: 23138970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation.
    Suwara MI; Vanaudenaerde BM; Verleden SE; Vos R; Green NJ; Ward C; Borthwick LA; Vandermeulen E; Lordan J; Van Raemdonck DE; Corris PA; Verleden GM; Fisher AJ
    Transpl Int; 2014 Aug; 27(8):857-67. PubMed ID: 24750386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing bronchiolitis obliterans syndrome (BOS) and chronic lung allograft dysfunction (CLAD) in children: what does the future hold?
    Snell GI; Paraskeva M; Westall GP
    Paediatr Drugs; 2013 Aug; 15(4):281-9. PubMed ID: 23605986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation.
    Sato M; Hwang DM; Ohmori-Matsuda K; Chaparro C; Waddell TK; Singer LG; Hutcheon MA; Keshavjee S
    J Heart Lung Transplant; 2012 Apr; 31(4):354-63. PubMed ID: 22330935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.